about
In vivo assessment of cold stimulation effects on the fat fraction of brown adipose tissue using DIXON MRI.Fusion of positron emission tomography (PET) and gene array data: a new approach for the correlative analysis of molecular biological and clinical data.Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis.Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection?Parametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours.Application of F-18-sodium fluoride (NaF) dynamic PET-CT (dPET-CT) for defect healing: a comparison of biomaterials in an experimental osteoporotic rat model.Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.Measurement of hypoxia-related parameters in three sublines of a rat prostate carcinoma using dynamic (18)F-FMISO-Pet-Ct and quantitative histology.Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma.Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities.Machine learning-based kinetic modeling: a robust and reproducible solution for quantitative analysis of dynamic PET data.Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS).The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction.Vemurafenib and ipilimumab: A promising combination? Results of a case seriesFractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab.Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers.The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.Dynamic (18)F-fluorodeoxyglucose positron emission tomography/CT in hibernoma: Enhanced tracer uptake mimicking liposarcoma.The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas.PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome.Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRIComparison between 68Ga-bombesin (68Ga-BZH3) and the cRGD tetramer 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell lineUse of LDH and autoimmune side effects to predict response to ipilimumab treatment.Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG.Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma.[Malignant melanoma : Current status].Angiopoietin-2 overexpression in morris hepatoma results in increased tumor perfusion and induction of critical angiogenesis-promoting genes.Angiostatin overexpression in Morris hepatoma results in decreased tumor growth but increased perfusion and vascularization.18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.(18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial.68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG.The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions.Dynamic PET with (18)F-Deoxyglucose (FDG) and quantitative assessment with a two-tissue compartment model reflect the activity of glucose transporters and hexokinases in patients with colorectal tumors.Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib.Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study.Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.
P50
Q31114992-52421416-8F78-408B-B70D-A2E58E7D43DEQ31120845-59B5D747-7E12-4A28-B001-F147FC607CC7Q32053919-F87E64E2-14A6-4FDA-BA57-85EF467E1BAEQ33269026-48BA167F-9818-4824-9844-26A56E312FD5Q33844776-F2D75752-BB0A-433E-93A0-700464F19CE4Q34409271-E9F37B38-1EF5-4272-AFB3-2C2EEFA1ADE8Q34544662-0C2C0B9D-FC98-4399-896C-81C17B58625AQ35744761-8DA3ECD5-9507-48FA-8F4D-AC474DCE41FEQ36205152-C92C32C6-C4F1-4B63-A3DD-B9E76F87048FQ36205157-A51BCC28-8CEB-4770-B731-9E85F4EF5C2CQ36335660-79587463-D104-4D7C-B151-55B05F4B361EQ36472317-D7C22EB8-6F6A-4D4F-A67E-66ED57D00F0DQ36570026-FF2EFB1D-7A4C-4A85-A6EA-368C5B467C4DQ36821040-B419CF62-0FD8-4B89-96CB-0E3BED302F23Q37139226-5402258E-8B49-4724-B9AB-38D10CF6FD6AQ37255453-3F60975D-FBF7-4196-8AA9-4101954CF365Q37389930-3E8107E5-6682-4CC7-9139-25733D236786Q37417787-5E76E6CC-6B05-4D9E-9F6F-474C38D83AA8Q37735719-98119034-AC2B-4793-AF7D-A298F1E9664BQ38389152-37B76FD1-873C-4663-B556-B31EE0B45B6BQ38619857-53E9E1BB-D96E-4C1D-9E94-91FE6AFF4092Q39418313-EE0A5B1E-B9C1-4C50-9214-311BE6BD1C73Q39532055-183749A2-EFFF-402F-8DA8-1497BF88B7FBQ39554739-258EE334-97F8-4679-8667-700885CF5A70Q39874031-84E0D34A-3D5A-4759-AA63-AD77CA4700EAQ40093371-E4F4883B-6461-4D7C-9484-33FD66EB681FQ40113867-3FD1B86B-2378-4E4C-AFEA-6F383EF5774CQ40235255-DEEA8703-9AFD-42C6-97B2-C62C435C0180Q40309334-E0975874-C392-448A-A5D5-80F4E16F1D86Q40404841-1B03D68C-5CAA-4DF1-8B5B-3F88FC9BB2D1Q41067892-3AD7A0F0-189D-44EA-A6FA-F4C9AF0F5211Q41180773-402FF570-8BE5-4F21-A661-69EBAE500B32Q41201314-81E0B39B-E7B0-4AD8-B3B6-5C9ACDFE7964Q41686423-D6170797-0730-4619-ADAE-3C77E9908E8DQ42626389-68CB9711-BBB7-41EF-AE7B-D46946C442CBQ42673890-2FBC7B71-4313-435E-9BAF-BEB9442FFFEBQ42966154-48627462-80A4-4706-988E-24A2043976C2Q43013544-882412B9-2607-484B-987F-7FD28F217827Q43115501-0B34F9DF-9C3E-4056-99DB-DE7D04650F76Q43119285-8E730B39-022E-47FB-9491-075FE306B3E9
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Antonia Dimitrakopoulou-Strauss
@ast
Antonia Dimitrakopoulou-Strauss
@en
Antonia Dimitrakopoulou-Strauss
@es
Antonia Dimitrakopoulou-Strauss
@nl
type
label
Antonia Dimitrakopoulou-Strauss
@ast
Antonia Dimitrakopoulou-Strauss
@en
Antonia Dimitrakopoulou-Strauss
@es
Antonia Dimitrakopoulou-Strauss
@nl
prefLabel
Antonia Dimitrakopoulou-Strauss
@ast
Antonia Dimitrakopoulou-Strauss
@en
Antonia Dimitrakopoulou-Strauss
@es
Antonia Dimitrakopoulou-Strauss
@nl
P1053
E-6314-2014
P106
P1153
7003424339
P21
P214
129144647639184535293
P2456
P31
P3829
P496
0000-0003-0338-9472
P735
P7859
viaf-129144647639184535293